Home Biosimilar Antibodies Others Others Bivatuzumab (Anti-CD44v6)
For research use only. Not for use in humans.

Bivatuzumab (Anti-CD44v6)

Synonyms: BIWA 4; Anti-CD44 Recombinant Antibody

Bivatuzumab (Anti-CD44v6) is a humanized monoclonal antibody targeting against CD44v6 that could acts as a sarcoma target for CAR-redirected CIK cells. MW:145.5 KD.

Bivatuzumab (Anti-CD44v6)

Quality Control

Batch: Purity: 99% Protein concentration: 9.057mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Bivatuzumab (Anti-CD44v6) is a humanized monoclonal antibody targeting against CD44v6 that could acts as a sarcoma target for CAR-redirected CIK cells. MW:145.5 KD.

Product Details

CAS No. 214559-60-1
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02254018 COMPLETED Drug: bivatuzumab mertansine Head and Neck Neoplasms Boehringer Ingelheim 2002-09-01 PHASE1
NCT02254031 TERMINATED Drug: bivatuzumab mertansine Breast Neoplasms Boehringer Ingelheim 2003-07-01 PHASE1
NCT02254005 COMPLETED Drug: bivatuzumab mertansine Breast Neoplasms Boehringer Ingelheim 2002-10-01 PHASE1
NCT02254044 TERMINATED Drug: bivatuzumab mertansine Carcinoma, Squamous Cell Boehringer Ingelheim 2003-10 PHASE1

(data from https://clinicaltrials.gov, updated on 2023-10-24)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.